Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19926284 | 0.61 | CYP2A6 (0.37) | CYP2A6DRD2DRD3CA1CA2 | |
| SCHEMBL1435831 | 0.61 | ALDH1A1 (0.39) | CYP2A6DRD2DRD3CA1CA2 | |
| SCHEMBL20204992 | 0.61 | CA2 (0.40) | CYP2A6CA1CA2VCAM1 | |
| SCHEMBL28971640 | 0.58 | TSHR (0.63) | CYP2A6MAOBDRD2DRD3CA2 | |
| SCHEMBL6739755 | 0.58 | — | — | |
| SCHEMBL15619538 | 0.58 | IMPDH2 (0.32) | MAOBDRD2DRD3CA1CA2 | |
| SCHEMBL9289 | 0.57 | TSHR (0.61) | DRD2DRD3 | |
| Water SCHEMBL28137572 | 0.57 | TSHR (0.61) | DRD2DRD3 | |
| SCHEMBL2817154 | 0.57 | TSHR (0.61) | DRD2DRD3 | |
| Bromide SCHEMBL17202846 | 0.57 | PNMT (0.52) | CYP2A6DRD2DRD3CA2PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116670115-A | Process for preparing anthranilic acid/anthranilic acid amide compounds and intermediates thereof | 皮埃企业有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-8163740-B2 | 6-substituted benzoxazines | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | HTR5A, NPY5R, GABRA5 | CYP2A6 379/4885MAOB 161/4885DRD2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.